Jpmorgan Chase & CO Mersana Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 50,704 shares of MRSN stock, worth $468,504. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,704
Previous 2,534,447 98.0%
Holding current value
$468,504
Previous $3.62 Million 99.53%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$0.34 - $1.4 $844,472 - $3.48 Million
-2,483,743 Reduced 98.0%
50,704 $17,000
Q4 2024

Feb 12, 2025
BUY
$1.42 - $2.68 $259,984 - $490,675
183,088 Added 7.79%
2,534,447 $3.62 Million
Q3 2024

Dec 26, 2024
BUY
$1.23 - $2.25 $460,585 - $842,535
374,460 Added 18.94%
2,351,359 $4.44 Million
Q3 2024

Nov 08, 2024
BUY
$1.23 - $2.25 $460,585 - $842,535
374,460 Added 18.94%
2,351,359 $4.44 Million
Q2 2024

Dec 26, 2024
SELL
$2.0 - $4.45 $748,920 - $1.67 Million
-374,460 Reduced 15.93%
1,976,899 $3.97 Million
Q2 2024

Aug 12, 2024
BUY
$2.0 - $4.45 $1.1 Million - $2.45 Million
549,559 Added 38.5%
1,976,899 $3.97 Million
Q1 2024

Dec 26, 2024
SELL
$2.16 - $5.94 $2 Million - $5.49 Million
-924,019 Reduced 39.3%
1,427,340 $6.39 Million
Q1 2024

May 10, 2024
BUY
$2.16 - $5.94 $2.91 Million - $8.01 Million
1,348,517 Added 1710.82%
1,427,340 $6.39 Million
Q4 2023

Dec 26, 2024
SELL
$1.11 - $2.34 $2.52 Million - $5.32 Million
-2,272,536 Reduced 96.65%
78,823 $182,000
Q4 2023

Feb 12, 2024
SELL
$1.11 - $2.34 $208,893 - $440,369
-188,192 Reduced 70.48%
78,823 $182,000
Q3 2023

Nov 14, 2023
SELL
$1.06 - $3.91 $1.25 Million - $4.6 Million
-1,176,779 Reduced 81.51%
267,015 $339,000
Q2 2023

Aug 11, 2023
BUY
$3.08 - $9.55 $4.07 Million - $12.6 Million
1,322,229 Added 1087.67%
1,443,794 $4.75 Million
Q1 2023

May 18, 2023
BUY
$4.0 - $7.02 $459,520 - $806,457
114,880 Added 1718.47%
121,565 $499,000
Q1 2023

May 11, 2023
SELL
$4.0 - $7.02 $1.52 Million - $2.67 Million
-380,138 Reduced 98.27%
6,685 $27,000
Q4 2022

Feb 13, 2023
BUY
$5.65 - $7.86 $1.85 Million - $2.57 Million
326,697 Added 543.35%
386,823 $2.27 Million
Q3 2022

Nov 14, 2022
SELL
$4.63 - $8.0 $1.81 Million - $3.13 Million
-391,013 Reduced 86.67%
60,126 $406,000
Q2 2022

Aug 11, 2022
BUY
$2.84 - $5.0 $401,888 - $707,550
141,510 Added 45.7%
451,139 $2.09 Million
Q1 2022

May 11, 2022
BUY
$3.74 - $6.63 $1.04 Million - $1.84 Million
278,047 Added 880.4%
309,629 $1.24 Million
Q4 2021

Feb 10, 2022
BUY
$5.48 - $9.86 $350 - $631
64 Added 0.2%
31,582 $197,000
Q3 2021

Nov 12, 2021
BUY
$8.56 - $14.47 $269,794 - $456,065
31,518 New
31,518 $297,000

Others Institutions Holding MRSN

# of Institutions
88
Shares Held
94.3M
Call Options Held
34.3K
Put Options Held
14K
View Full List

About Mersana Therapeutics, Inc.

MRSN Quotes by TradingView
  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $898M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email